Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
作者： U. Martin , S. Fischer , U. Kohnert , U. Opitz , R. Rudolph
DOI: 10.1007/BF00167579
关键词: Pharmacology 、 Potency 、 Fibrinolysis 、 Lagomorpha 、 Thrombolysis 、 Activator (genetics) 、 Immunology 、 Biology 、 Plasminogen activator 、 Recombinant DNA 、 Pharmacokinetics
摘要: Recombinant tissue-type plasmogen activator (rt-PA) was produced in Escherichia coli cells order to obtain an unglycosylated rt-PA (BM 06.021) with increased thrombolytic potency due altered pharmacokinetic properties. The pharmacokinetics were studied rabbits upon intravenous infusion of 200 kU/kg over 30 min. dose-response effects evaluated a rabbit model 125I-labeled venous thrombi 4 h. after bolus injection BM 06.021 investigated canine coronary artery thrombosis. All studies performed comparing glycosylated (alteplase).
springer.com
sci-hub.se 参考文章(30)
U. Martin, B. Kaufmann, J. Köhler, G. Sponer, K. Strein, Pharmacokinetics of t-PA produced in E. coli, in conscious dogs Fibrinolysis and Proteolysis. ,vol. 4, pp. 90- ,(1990) , 10.1016/0268-9499(90)90255-I
R.G. Wilcox, C.G. Olsson, A.M. Skene, G. Von Der Lippe, G. Jensen, J.R. Hampton, For The Asset Study Group, TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION: Anglo-Scandinavian Study of Early Thrombolysis (ASSET) The Lancet. ,vol. 332, pp. 525- 530 ,(1988) , 10.1016/S0140-6736(88)92656-6
J Kuiper, M Otter, D C Rijken, T J van Berkel, Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. Journal of Biological Chemistry. ,vol. 263, pp. 18220- 18224 ,(1988) , 10.1016/S0021-9258(19)81348-0
E H Ohlstein, S Horohonich, R J Shebuski, G A Kopia, L J Kopaciewicz, B L Storer, Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy Journal of Pharmacology and Experimental Therapeutics. ,vol. 250, pp. 887- 895 ,(1989)
J M Smith, P J Bugelski, B L Storer, R J Shebuski, J R Granett, Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. Journal of Pharmacology and Experimental Therapeutics. ,vol. 246, pp. 790- 796 ,(1988)
D Pennica, J M Stassen, J Salwa, W F Bennett, D Collen, D Tajiri, B J Marafino, F De Cock, S Builder, J Ogez, Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. Journal of Pharmacology and Experimental Therapeutics. ,vol. 231, pp. 146- 152 ,(1984)
H. Y. Huang, Unified approach to quadratically convergent algorithms for function minimization Journal of Optimization Theory and Applications. ,vol. 5, pp. 405- 423 ,(1970) , 10.1007/BF00927440
A. Clauss, Rapid physiological coagulation method in determination of fibrinogen Acta Haematologica. ,vol. 17, pp. 237- 246 ,(1957) , 10.1159/000205234
Gunnar POHL, Lennart KENNE, Bo NILSSON, Monica EINARSSON, Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator FEBS Journal. ,vol. 170, pp. 69- 75 ,(1987) , 10.1111/J.1432-1033.1987.TB13668.X
D.C. Rijken, M. Otter, J. Kuiper, Th.J.C. van Berkel, Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thrombosis Research. ,vol. 57, pp. 63- 71 ,(1990) , 10.1016/0049-3848(90)90379-Q